Program Description
Immunoglobulin A nephropathy (IgAN) often begins asymptomatically but can progress to end-stage renal disease (ESRD) in about 40% of patients. This progression is associated with impaired health-related quality of life and significant costs as patients receiving nonhospital-based care can exceed hundreds of thousands of dollars per year, with additional financial burdens on caregivers and society. The cost of supportive therapies must also be factored for patients with IgAN as they are likely to require prolonged administration throughout the patient’s disease course. The treatment goal for patients with IgAN is to slow progression, reduce kidney damage, and delay or prevent ESRD. Although FDA-approved products are limited for IgAN, there are a number of agents under investigation, and managed care professionals must prepare for the future place of these medications in supportive care pathways for patients with IgAN to improve disease management and patient access to treatment. This activity will review recommended guidelines for the identification and management of patients with IgAN as well as recently approved products and potential therapies under investigation and their targeted pathways.
Target audience: Managed care pharmacists, specialty pharmacists
Type of activity: Application
Release date: March 1, 2023
Expiration date: March 1, 2024
Time to complete activity: 2.0 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the pathophysiology and disease progression of IgA nephropathy (IgAN) and the clinical challenges and burden for patients.
- Explain the treatment goals, the disease-specific relevance of proteinuria, and other recommendations from the KDIGO guidelines for the treatment of IgAN.
- Analyze the clinical trial data, mechanisms of action, and cellular targets for emerging pharmacologic treatments in IgAN.
- Identify disease management protocols and care pathways that promote early diagnosis and treatment to delay or prevent disease progression in IgAN.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
